Nanjing Well Pharmaceutical Group Co.,Ltd. (SHA:603351)
China
· Delayed Price · Currency is CNY 26.52
-0.27 (-1.01%)
Mar 11, 2026, 11:29 AM CST
SHA:603351 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 147.59 | 146.42 | 112.2 | 95.03 | 101.37 | 100.45 | Upgrade
|
| Depreciation & Amortization | 115.49 | 115.49 | 71.74 | 71.76 | 42.81 | 34.34 | Upgrade
|
| Other Amortization | 0.66 | 0.66 | 1.03 | 1.1 | 1.13 | 1.05 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | 0 | 0.05 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.17 | 0.17 | 0.18 | 0.1 | 1.91 | 1.96 | Upgrade
|
| Loss (Gain) From Sale of Investments | -12 | -12 | -1.44 | 0.11 | -2.25 | -11.97 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.34 | 0.34 | 0.29 | -4.48 | 2.35 | 1.15 | Upgrade
|
| Other Operating Activities | 1.69 | 20.28 | 14.26 | 12.21 | 6.17 | 5.28 | Upgrade
|
| Change in Accounts Receivable | -13.57 | -13.57 | -31.41 | 34.17 | -105.72 | 71.34 | Upgrade
|
| Change in Inventory | -40.46 | -40.46 | -9.38 | -22.77 | -29.18 | -0.55 | Upgrade
|
| Change in Accounts Payable | -3.98 | -3.98 | -43.96 | -106.45 | -42.06 | -110.25 | Upgrade
|
| Change in Other Net Operating Assets | 3.36 | 3.36 | 10.46 | 28.06 | 15.44 | - | Upgrade
|
| Operating Cash Flow | 204.37 | 221.79 | 120.24 | 108.99 | -11.54 | 93.3 | Upgrade
|
| Operating Cash Flow Growth | -9.52% | 84.45% | 10.33% | - | - | -28.06% | Upgrade
|
| Capital Expenditures | -57.47 | -51.46 | -73.07 | -233.9 | -235.62 | -282.44 | Upgrade
|
| Investment in Securities | -30.4 | -18.53 | 5.23 | -4.73 | 172.72 | 118.87 | Upgrade
|
| Other Investing Activities | 0.72 | -0.5 | - | 0.95 | -5.07 | -1.87 | Upgrade
|
| Investing Cash Flow | -87.14 | -70.48 | -67.84 | -237.68 | -67.97 | -165.44 | Upgrade
|
| Long-Term Debt Issued | - | 381.02 | 483.15 | 480.87 | 220.06 | 137.11 | Upgrade
|
| Total Debt Issued | 559.13 | 381.02 | 483.15 | 480.87 | 220.06 | 137.11 | Upgrade
|
| Long-Term Debt Repaid | - | -387.19 | -434.1 | -268.19 | -157.47 | -122.98 | Upgrade
|
| Total Debt Repaid | -410.69 | -387.19 | -434.1 | -268.19 | -157.47 | -122.98 | Upgrade
|
| Net Debt Issued (Repaid) | 148.45 | -6.16 | 49.05 | 212.68 | 62.59 | 14.13 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 49.27 | - | Upgrade
|
| Common Dividends Paid | -66.77 | -55.47 | -53.41 | -53.89 | -45.25 | -47.08 | Upgrade
|
| Other Financing Activities | -2.16 | -1.4 | 9.16 | 2.4 | 3.95 | 0.35 | Upgrade
|
| Financing Cash Flow | 79.52 | -63.03 | 4.79 | 161.2 | 70.56 | -32.6 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.74 | 1.37 | 0.53 | 1.06 | -0.36 | -0.64 | Upgrade
|
| Net Cash Flow | 197.48 | 89.65 | 57.72 | 33.56 | -9.3 | -105.37 | Upgrade
|
| Free Cash Flow | 146.9 | 170.34 | 47.17 | -124.91 | -247.16 | -189.13 | Upgrade
|
| Free Cash Flow Growth | -9.60% | 261.09% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 11.17% | 13.14% | 4.08% | -11.24% | -23.71% | -25.70% | Upgrade
|
| Free Cash Flow Per Share | 1.08 | 1.26 | 0.35 | -0.93 | -1.85 | -1.45 | Upgrade
|
| Cash Income Tax Paid | 66.02 | 70.09 | 52.21 | -2.99 | 25.21 | 43.57 | Upgrade
|
| Levered Free Cash Flow | 110.01 | 122.94 | -23.51 | -90.86 | -214.39 | -3.9 | Upgrade
|
| Unlevered Free Cash Flow | 117.29 | 131.58 | -13.98 | -83.05 | -209.99 | -0.77 | Upgrade
|
| Change in Working Capital | -49.56 | -49.56 | -78.01 | -66.84 | -165.09 | -38.95 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.